Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF FEBRUARY 10, 2013 FBO #4096
SOURCES SOUGHT

65 -- iCell Cardiomyocytes

Notice Date
2/8/2013
 
Notice Type
Sources Sought
 
NAICS
541711 — Research and Development in Biotechnology
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 3900 NCTR Road, HFT-320, Bldg 50 | Rm 421, Jefferson, Arkansas, 72079, United States
 
ZIP Code
72079
 
Solicitation Number
FDA113788
 
Archive Date
3/6/2013
 
Point of Contact
Janice Heard, Phone: 215-717-3093
 
E-Mail Address
janice.heard@fda.hhs.gov
(janice.heard@fda.hhs.gov)
 
Small Business Set-Aside
Total Small Business
 
Description
THIS IS FOR MARKET RESEARCH PURPOSES ONLY: This Sources Sought notice is to determine the availability and capability of small businesses, under NAICS Code 541711 as an actual manufacturer for the requirement described below. The information being sought is for information and planning purposes only and shall not be construes as a commitment on the part of the Government to award a contract. The Government does not intend to pay for any information submitted as a result of this notice. Any response received will not be used as a proposal. The information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. After a review of the responses received, a solicitation may be published in FedBizOpps. However, responses to this notice will not be considered adequate responses to the solicitation. **THERE WILL BE NO QUESTIONS AND ANSWER PERIOD**No Phone calls will be accepted. Requirements: The U.S. Food and Drug Administration (FDA) is seeking a small business concerns capable of meeting the FDA's requirement for the iCell Cardiomyoctes.. The iCell® Cardiomyocytes must be highly purified human cardiomyocytes derived from iPS cells through proprietary differentiation and purification protocols. The cells must express monomeric red fluorescent protein (mRFP) and blasticidin resistance, both of which are under the control of the alpha-myosin heavy chain (Myh6) promoter that allows simultaneous cardiomyocyte purification and identification. The iCell Cardiomyocytes must be purified by Myh6. iCell Cardiomyocytes are a mixture of spontaneously electrically active atrial, nodal, and ventricular-like myocytes that possess typical electrophysiological characteristics and exhibit expected electrophysiological and biochemical responses upon exposure to exogenous agents. The cells are a reliable source of human cardiomyocytes suitable for use in targeted drug discovery, toxicity testing, and other life science research. Response Date: All information should be submitted via email and received by February 19, 2013, at 3:00 p.m. Eastern Time
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/NCTR/FDA113788/listing.html)
 
Place of Performance
Address: U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas, 72079, United States
Zip Code: 72079
 
Record
SN02983541-W 20130210/130208235557-bb8fbadad3e8b28c03e9d7e52ba47d31 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.